Search results
Results From The WOW.Com Content Network
340B DSH hospitals provide nearly twice as much care as non-340B hospitals – 41.9 percent versus 22.8 percent – to Medicaid beneficiaries and low-income Medicare patients. 340B hospitals provide 40 percent more uncompensated care as a percent of total patient care costs than non-340B hospitals – $24.6 billion to $17.5 billion.
The 340B Drug Pricing Program, administered by the Office of Pharmacy Affairs, resulted from enactment of Public Law 102-585, the Veterans Health Care Act of 1992, which is codified as Section 340B of the Public Health Service Act. Section 340B limits the cost of covered outpatient drugs to more than 18,000 eligible entities including ten types ...
The 340B drug pricing program, originally intended to help low-income and uninsured patients, has been exploited by special interests for profit, resulting in higher drug prices, taxes, and ...
Those covered entities then receive the difference between the reduced prices and the list prices for 340B eligible drugs in the form of rebates that count as revenue. [ 22 ] In November 2022, ADAP Advocacy formed the Ryan White Grantee 340B Patient Advisory Committee to address gaps in knowledge and awareness among patients, advocates ...
A big problem with 340B or similar programs is that pharmacies and hospitals can choose to bill for the discounted drugs at full price, defeating the purpose of the program to control drug prices and maintain affordability for low-income patients.
The Patient Self-Determination Act (PSDA) was passed by the United States Congress in 1990 as an amendment to the Omnibus Budget Reconciliation Act of 1990.Effective on December 1, 1991, this legislation required many hospitals, nursing homes, home health agencies, hospice providers, health maintenance organizations (HMOs), and other health care institutions to provide information about ...
The Medicare Improvements for Patients and Providers Act of 2008 ("MIPPA"), is a 2008 statute of United States Federal legislation which amends the Social Security Act. On July 15, 2008, President George W. Bush vetoed the bill. [1] On that same day the House of Representatives and the Senate voted to overturn the veto. [1] [2]
The bill also places a burden on any comparative effectiveness program to take into account factors contributing to differences in the treatment response, or the treatment preferences of patients. This would include patient-reported outcomes, genomics, personalized medicine, the unique needs of health disparity populations (sic.), and indirect ...